Zacks Investment Research·Sep 24, 2026
Here's Why You Should Retain Glaukos Stock in Your Portfolio for NowGlaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Glaukos is executing a compelling growth story, with revenue accelerating to $185.6M in 2026Q2 (up 49.5% YoY) and gross margin expanding to 81.7%, signaling strong product adoption and pricing power. Operating leverage is emerging as operating margin improved ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 49.5% YoY in 2026Q2, with gross margin expanding to 81.7% and operating margin improving to -9.3%, though net losses persist.
Glaukos focuses on developing novel therapies to advance the standard of care in the global ophthalmic market, enriching patient treatment alternatives.
The investment case for Glaukos is supported by solid fundamentals, valuation multiples, and analyst positioning, indicating potential growth.
Positive smart-money flows into Glaukos suggest institutional confidence in the company's long-term prospects.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | -$0.14+33.5% vs -$0.21 | $186M+23.0% vs $151M |
Q2 2026 Apr 29, 2026 | -$0.18+40.0% vs -$0.30 | $151M+9.9% vs $137M |
Q1 2026 Feb 17, 2026 | -$0.28-27.3% vs -$0.22 | $143M+4.9% vs $136M |
Q4 2025 Oct 29, 2025 | -$0.16+40.7% vs -$0.27 | $134M+3.2% vs $129M |
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening c.
Squarepoint Ops LLC reduced its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 86.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,167 shares of the medical instruments supplier's stock after selling 93,882 shares during the period.
Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,048 shares of the medical instruments supplier's stock, valued at approximately $7,973,000. Corient Private Wealth LP owned approximately 0.10% of Glaukos at the
Benchmark GKOS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Glaukos Corporation (GKOS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $163.75 | $9.66B | -49.92 | 32.33% | -36.99% | -26.38% | — | |
| $55.14 | $2.8B | -229.75 | 14.88% | 1.85% | 2.14% | — | |
| $14.94 | $1.73B | -12.25 | 8.28% | -21.25% | -44% | — | |
| $16.50 | $1.13B | -5.43 | 7.93% | -6.08% | -45.97% | — | |
| $69.97 | $2.02B | 14.31 | 13.6% | 15.03% | 17.62% | — | |
| $85.15 | $49.03B | 46.53 | 11.55% | 15.43% | 9.66% | — |
Glaukos Corporation (GKOS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Glaukos Corporation (GKOS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 3, 2026·SEC
May 4, 2026·SEC
Get notified when GKOS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Glaukos Corporation (GKOS) stock FAQ — growth, dividends, profitability & financials explained
Glaukos Corporation (GKOS) reported $612.8M in revenue for fiscal year 2025. This represents a 25130% increase from $2.4M in 2012.
Glaukos Corporation (GKOS) grew revenue by 32.3% over the past year. This is strong growth.
Glaukos Corporation (GKOS) reported a net loss of $188.0M for fiscal year 2025.
Glaukos Corporation (GKOS) has a return on equity (ROE) of -26.4%. Negative ROE indicates the company is unprofitable.
Glaukos Corporation (GKOS) had negative free cash flow of $12.2M in fiscal year 2025, likely due to heavy capital investments.
